The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Agenus; OncXerna Therapeutics; Treos Bio; Verastem
Stock and Other Ownership Interests - Agenus; OncXerna Therapeutics; Treos Bio; Verastem
Consulting or Advisory Role - C4 Therapeutics
Phase 1 first-in-human trial of MTB-9655, the first oral inhibitor of ACSS2, in patients with advanced solid tumors.
 
Ruth Perets
No Relationships to Disclose
 
Ravit Geva
Leadership - Pyxis
Stock and Other Ownership Interests - BOL Pharma; Pyxis
Honoraria - Janssen; Medison; Merck; MSD; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; BOL Pharma; Eisai; MSD; Rhenium Medical; Roche
Travel, Accommodations, Expenses - Medison; Takeda (Inst)
 
Meredith McKean
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Castle Biosciences (Inst); Eisai (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst)
Research Funding - Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Oncorus (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Takeda (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Andreas Goutopoulos
Employment - MetaboMed
Leadership - Actithera; MetaboMed
Stock and Other Ownership Interests - MetaboMed
Consulting or Advisory Role - FoRx Therapeutics
Patents, Royalties, Other Intellectual Property - EMD Serono; Metabomed
Travel, Accommodations, Expenses - MetaboMed
 
Omri Erez
Employment - MetaboMed
Stock and Other Ownership Interests - MetaboMed
 
Monica Phadnis
Employment - MetaboMed
Stock and Other Ownership Interests - MetaboMed
 
Hagop Youssoufian
No Relationships to Disclose
 
Brian E. Schwartz
Employment - MetaboMed
Leadership - MetaboMed
Stock and Other Ownership Interests - MetaboMed
 
Vikram Kansra
Consulting or Advisory Role - MetaboMed
 
Ali Fattaey
Employment - MetaboMed
Leadership - MetaboMed
Stock and Other Ownership Interests - MetaboMed